As this unprecedented year comes to a close, the Office of Communications is rerunning some of the big stories of 2020 that highlight the incredible work of the UMass Medical School community. From the first-in-the-nation early graduation of our medical students to the essential clinical research that lead to a SARS-CoV-2 vaccine, from the tremendous growth of the institution’s research funding to ground broken on the new research and education building, we have so much to be proud of. Look for these stories on UMassMed News between Dec. 21 and Jan. 1. We hope you enjoy them!
|
According to the Association of University Technology Managers (AUTM), the University of Massachusetts ranked fourth among all U.S. institutions and third among universities for generating income from the licensing of faculty-derived discoveries and products in FY 2018, the most recent year for which figures are available. UMass reported licensing revenue of approximately $146 million; the only universities that reported higher totals for that time period were the University of California system and Northwestern University. The City of Hope Medical Center/Beckman Research Institute in California ranked first.
“The FY18 AUTM ranking reflects the significance and appeal of the world-class biomedical research underway at UMass Medical School,” said Chancellor Michael F. Collins. “The global life sciences sector has taken notice, time and time again, of the highly specialized and best-in-class expertise and capabilities of our faculty, our robust innovation and business development platform, and the unique spirit of collaboration that is a hallmark of UMass Medical School. We are proud to be ranked among the top research universities in the nation and proud that the work our research community undertakes every day contributes tangibly and powerfully to the pipeline of discoveries aimed at improving human health.”
The Medical School accounted for 99 percent of the UMass system’s FY 2018 licensing revenue.
AUTM publishes annual rankings related to revenue generated from licensing activities. In this survey, respondents comprised 170 universities, 27 hospitals and research institutes, and one technology management firm. The rankings serve as an indicator of the strength and impact of a university’s research and development portfolio and commercialization efforts.
For several years, the Medical School has helped to drive and sustain the position of UMass among an elite group of institutions and universities that have been able to generate substantial revenues from licensing and commercialization activities.
